Antimicrobial agents target essential bacterial structures and processes: cell wall synthesis (beta-lactams, glycopeptides), protein synthesis (30S: aminoglycosides, tetracyclines; 50S: macrolides, clindamycin, linezolid), DNA replication/repair (fluoroquinolones target topoisomerase II/IV; metronidazole generates DNA-damaging free radicals), folate synthesis (trimethoprim/sulfamethoxazole), and cell membrane integrity (daptomycin, polymyxins). Antibiotic resistance emerges through four primary mechanisms: (1) Enzymatic degradation — beta-lactamases (including extended-spectrum beta-lactamases [ESBLs] and carbapenemases [KPC, NDM, OXA-48]) hydrolyze the beta-lactam ring; (2) Target modification — altered penicillin-binding proteins (PBP2a in MRSA, encoded by mecA gene), ribosomal methylation (erm genes conferring macrolide resistance); (3) Efflux pumps — actively transport antibiotics out of the cell (tetracycline resistance, fluoroquinolone resistance); (4) Decreased permeability — porin mutations reducing outer membrane drug entry (carbapenem-resistant Enterobacterales). Key resistant organisms threatening clinical outcomes: MRSA (methicillin-resistant Staphylococcus aureus — mecA-mediated PBP2a), VRE (vancomycin-resistant Enterococcus — vanA/vanB gene clusters modifying D-Ala-D-Ala to D-Ala-D-Lac), ESBL-producing Enterobacterales (CTX-M enzymes hydrolyzing third-generation cephalosporins — treat with carbapenems), CRE (carbapenem-resistant Enterobacterales — limited therapeutic options including ceftazidime-avibactam, meropenem-vaborbactam), and MDR Pseudomonas aeruginosa. Clostridioides difficile infection (CDI) results from antibiotic-mediated disruption of colonic microbiota, allowing C. difficile spore...